Synthaverse S.A.

Warsaw Stock Exchange SVE.WA

Synthaverse S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2023: 3.52%

Synthaverse S.A. Return on Capital Employed (ROCE) is 3.52% for the year ending December 31, 2023, a -46.91% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • Synthaverse S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 6.62%, a 0.82% change year over year.
  • Synthaverse S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 6.57%, a -19.74% change year over year.
  • Synthaverse S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 8.19%, a -14.43% change year over year.
  • Synthaverse S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 9.57%, a 117.21% change year over year.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
SV Wall Street
Warsaw Stock Exchange: SVE.WA

Synthaverse S.A.

CEO Mr. Mieczyslaw Starkowicz
IPO Date July 29, 2011
Location Poland
Headquarters Ul. Uniwersytecka 10
Employees 239
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Cleaning Supplies Drugstores & Retail Pharmacies Fertilizers Personal Care Plastics Vaccines
Description

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company's prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma. In addition, the company provides reagents, such as horse serum, bovine serum, calf serum, trypsin, PBS fluid, hanks fluid, parker's fluid, Eagle 1959 medium, Rpmi 1640 medium, and Ogawa medium, as well as pseudo cholinesterase, Ox fibrinogen, and rabbit complements. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. The company was founded in 1944 and is based in Lublin, Poland.

StockViz Staff

February 6, 2025

Any question? Send us an email